Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association. Laura M. Mann ...

Mental Health, CUNY SPH doctoral alum Dana Watnick and team sought to explore local understandings of depression and mental ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...

Physicians and their patients report that engagement in an HIV-based community rivals drug effectiveness in the ongoing efforts to curtail an epidemic. Confronting the HIV Epidemic: There's an App ...

July 23, 2024 — Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global ...

Preexposure prophylaxis (PrEP) use increased between 2013 and 2023 ... Mann et al, Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023, JAMA (2024).